If you saw headlines about the FDA “banning compounded semaglutide” and felt a wave of panic, you’re not alone. Most of those headlines missed a critical detail. There are two very different types of compounding pharmacies under US law, and the FDA proposal that surfaced in May 2026 targets only one of them.
Most Traqr users get their compounded semaglutide through an individual-prescription pharmacy. If that’s you, your situation is almost certainly different from what the headlines described.
The two types of compounding pharmacies
US law defines compounding pharmacies under two separate sections of the Federal Food, Drug, and Cosmetic Act. They look similar from the outside, but they operate under completely different regulatory frameworks.
503A pharmacies — individual-prescription compounders
A 503A pharmacy compounds medications for a specific, named patient under a valid prescription from a licensed prescriber. Picture an independent pharmacy that prepares a custom-dose injectable because a commercial product is unavailable or isn’t appropriate for you.
Key facts about 503A pharmacies:
- They must have a patient-specific prescription before compounding anything.
- They are regulated primarily by state pharmacy boards, not the FDA directly.
- They are not required to register with the FDA or follow the same current Good Manufacturing Practice (cGMP) standards that drug manufacturers follow.
- They cannot make large batches for general distribution. Every compound is tied to a specific patient’s prescription.
503B outsourcing facilities — large-scale, bulk compounders
A 503B outsourcing facility is a completely different category. These are large-scale manufacturers that produce compounded drugs in bulk and sell them to hospitals, clinics, and healthcare providers without patient-specific prescriptions.
Key facts about 503B facilities:
- They must register with the FDA and follow cGMP standards.
- They can produce large quantities of a drug and sell it wholesale to providers.
- They operate more like pharmaceutical manufacturers than neighborhood pharmacies.
- Large specialty pharmacy networks and companies like Halozyme often operate under 503B designations for their bulk compounding operations.
What the FDA proposal actually says
In May 2026, the FDA proposed adding semaglutide to a list of drugs that 503B outsourcing facilities cannot compound. The agency’s stated reasoning: now that commercially-manufactured brand semaglutide (Ozempic, Wegovy) is no longer in shortage, 503B facilities no longer have the legal basis to compound it at scale.
This proposal specifically and exclusively targets 503B outsourcing facilities. It does not directly regulate 503A individual-prescription pharmacies.
Under current legal interpretation, 503A pharmacies still may compound semaglutide for individual patients when a prescriber determines it’s appropriate for that specific patient. The legal pathway for 503A compounding is entirely separate from what the FDA addressed in the May 2026 notice.
What this actually means for your supply
Here’s where things stand based on what’s known today.
| 503A (individual-prescription) | 503B (outsourcing/bulk) | |
|---|---|---|
| FDA May 2026 proposal | Not directly targeted | Targeted — affected |
| Regulatory authority | State pharmacy boards | FDA (federal) |
| Prescription required? | Yes — patient-specific | No |
| Risk to supply right now | Low — but watch for state-level changes | High for bulk-sourced product |
If you get your compounded semaglutide from a 503A pharmacy: Your supply is not directly affected by this specific proposal. Your pharmacy compounds for you specifically, under your prescription. That legal pathway remains open.
If you are unsure which type of pharmacy you use: Ask directly — “Are you a 503A compounding pharmacy or a 503B outsourcing facility?” Any reputable pharmacy will answer immediately. You can also check your prescription: 503A fills require a patient-specific prescription tied to your name and your prescriber.
What to watch going forward
The rules here are still moving. A few things are worth keeping an eye on.
Even though the FDA proposal doesn’t target 503A pharmacies, individual states regulate compounding under their own pharmacy practice acts. If your state board issues guidance restricting compounded semaglutide, that affects 503A fills in your state regardless of the federal situation.
Some prescribers may also become more conservative about writing compounded-semaglutide prescriptions in response to the broader regulatory climate, even where it remains legal.
Then there’s the timeline. The May 2026 notice was a proposal, not a final rule. The FDA must complete a notice-and-comment rulemaking process before any final rule takes effect, and that typically takes months, sometimes longer. Track fda.gov or subscribe to Traqr updates for developments.
One last thing to watch is commercial availability. The FDA’s justification for the 503B restriction rests on the fact that commercial semaglutide is no longer in shortage. If that supply situation changes, the legal rationale for compounding shifts in both directions.
The bottom line
Most Traqr users on compounded semaglutide get their medication through 503A individual-prescription pharmacies. The FDA’s May 2026 proposal targets 503B outsourcing facilities, a different category operating under a different set of federal rules.
Don’t assume your supply is about to disappear based on these headlines. Do confirm with your pharmacy which regulatory framework they operate under, and stay informed as the rulemaking process develops.
If you have questions about your specific medication and treatment plan, talk to your prescribing clinician. Nothing in this article is legal or medical advice. It’s a plain-language explanation of regulatory categories to help you ask better questions and understand the news accurately.
Traqr users: you can log medication changes directly in the app. If your compounded semaglutide situation changes, update your medication log so your trend data stays accurate.